Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nicotinic Acetylcholine Receptor Alpha9-Alpha10 Subtype (nAChR α9α10)
- Target
- nAChR α9α10
- Molecular classification
- Ligand-gated ion channel, Nicotinic acetylcholine receptor, Pentameric ligand-gated ion channel
01
Overview
The nAChR α9α10 is a heteropentameric nicotinic acetylcholine receptor subtype composed of α9 and α10 subunits. It exhibits a unique pharmacological profile, being blocked by nicotine and having a mixed nicotinic-muscarinic pharmacology. It plays a crucial role in auditory processing, particularly in the inner ear, and is implicated in pain pathways. It represents a promising therapeutic target for preventing hearing loss and potentially for pain management.
- Other names
- α9α10 nAChRnAChR alpha9alpha10Acetylcholine Receptor Nicotinic Alpha9 Alpha10 Subunit
02
Mechanism of action
Ligand-gated ion channel activity modulation; receptor inhibition or activation depending on the specific ligand
03
Biological functions
Synaptic transmissionAuditory processingVestibular sensory processingEfferent auditory system functionIon channel activity
04
Disease associations
Hearing lossNoise-induced hearing lossPresbycusis (age-related hearing loss)Pain processing
05
Safety considerations
Potential for off-target effects due to structural similarities with other Cys-loop receptorsSelectivity challenges in drug development
06
Interacting drugs
Nicotine
5 more in the full profile.
Beyond the preview
Go deeper on Nicotinic Acetylcholine Receptor Alpha9-Alpha10 Subtype (nAChR α9α10).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Nicotinic Acetylcholine Receptor Alpha9-Alpha10 Subtype (nAChR α9α10).